ABO-incompatible liver transplantation – exploring utilitarian solutions to restricted access and organ shortages: A single-centre experience from Johannesburg, South Africa
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i3b.1211Keywords:
liver, transplant, ABO-incompatible, liver transplant, South Africa, adult, paediatricsAbstract
Background. Liver transplantation is the definitive management for severe acute liver failure refractory to supportive management, and end- stage chronic liver failure. Owing to a shortage of deceased liver donors, South Africa requires innovative techniques to broaden the donor pool.
Objectives. This study evaluated the outcomes of the Wits Transplant Unit ABO-incompatible liver transplant (ABOi-LT) programme. Methods. This retrospective record review compared all adult and paediatric patients receiving ABO-compatible (ABOc) and ABO-incompatible (ABOi) liver transplants from January 2014 to December 2021 with a minimum one-year follow-up. Primary outcomes were recipient and graft survival and secondary outcomes included vascular, enteric and biliary complications, relook surgery, acute cellular rejection (ACR) and lenghth of hospital stay. Cox proportional hazards regression was performed to examine the effect of ABO-compatibility group on recipient and graft survival. The relationship between the ABO-compatibility group and categorical outcomes was assessed by binomial regression.
Results. During the study period, 532 liver transplants were performed; 44/532 (8%) were ABOi of which 14/44 (32%) were paediatric and 30/44 (68%) adult recipients. Within the pediatric group, the proportion of transplants performed for acute liver failure was significantly higher in the ABOi group (7/14; 50%) compared with the ABOc group (33/207; 16%) (p=0.005). Comparable recipient and graft survival estimates were noted: one-, three- and five-year recipient survival in the ABOi group was 77% (95% confidence interval (CI) 44 - 92), 58% (95% CI 17 - 84) and 58% (95% CI 17 - 84) respectively. There were significantly increased relative risks of relook surgery for the ABOi group compared with the ABOc group, both overall (relative risk (RR) 1.74; 95% CI 1.10 - 2.75) and at 90 days (RR 2.28; 95% CI 1.27 - 4.11); and also, for pre-discharge bloodstream infection (BSI), (RR 1.84; 95% CI 1.11 - 3.06). In adults, there were significantly more acute indications for liver transplantation in the ABOi (10/30; 33%) compared with the ABOc group (26/281; 9%) (p=0.0007) with the most common cause being drug or toxin ingestion (16/36; 44%). For the ABOi group, recipient survival estimates (95% CI) at 1, 3 and 5 years were 71% (50 - 84), 63% (41 - 78) and 58% (37 - 75) which, as noted with complication rates, were similar between ABO groups.
Conclusion. This study confirms ABOi-LT as a feasible option to increase the liver donor pool in this organ-depleted setting as recipient survival and complication rates were similar between ABO-compatibility groups.
References
Zhang T, Dunson J, Kanwal F, et al. Trends in outcomes for marginal allografts in liver transplant. JAMA Surg 2020;155(10):926-932. https://doi.org/10.1001/jamasurg.2020.2484
Lee EC, Kim SH, Park SJ. Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis. World J Gastroenterol 2017;23(35):6516-6533. https://doi. org/10.3748/wjg.v23.i35.6516
Markiewicz-Kijewska M, Kaliciński P, Torres Canizales J, et al. Abo incompatible liver transplantation in children: A 20 year experience from centres in the transplant child European Reference Network. Children 2021;8(9):760. https://doi.org/10.3390/children8090760
Zhang Y, Zhang J, Yi H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: A phase I/II randomized, open-label, controlled trial. Stem Cell Res Ther 2021;12(1). https://doi.org/10.1186/s13287-021-02246-4
Yadav DK, Hua YF, Bai X, et al. ABO-incompatible adult living donor liver transplantation in the era of rituximab: A systematic review and meta-analysis. Gastroenterol Res Pract 2019;8589402. https:// doi.org/10.1155/2019/8589402
Egawa H, Teramukai S, Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: A Japanese multicenter study. Am J Transp 2014;14(1):102-114. https://doi.org/10.1111/ajt.12520
Troisi R, Noens L, Montalti R, et al. Abo-mismatch adult living donor liver transplantation using antigen-specific immunoadsorption and quadruple immunosuppression without splenectomy. Liver Transp 2006;12(9):1412-1417. https://doi.org/10.1002/lt.20727
Lee C-F, Cheng C-H, Wang Y-C, et al. Adult living donor liver transplantation across ABO- incompatibility. Medicine 2015;94(42). https://doi.org/10.1097/md.0000000000001796
Contreras AG, McCormack L, Andraus W, et al. Current status of liver transplantation in Latin America. Int J Sur 2020;82:14-21. https://doi.org/10.1016/j.ijsu.2020.03.039
Ulasi I, Ijoma C, Ifebunandu N, et al. Organ donation and transplantation in Sub-Saharan Africa: Opportunities and challenges. Organ Donation and Transplantation. IntechOpen 2021. https://doi. org/10.5772/intechopen.94986 (accessed 16 March 2023).
Tager S, Etheredge HR, Fabian J, Botha JF. Reimagining liver transplantation in South Africa: A model for justice, equity and capacity building - the Wits Donald Gordon Medical Centre experience. S Afr Med J 2019;109:84-88. https://doi.org/10.7196/SAMJ.2019.v109i2.13835
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381. https://doi.org/10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95. https://doi.org/10.1016/j.jbi.2019.103208
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 2006;6:783-790. https://doi.org/10.1111/j.1600- 6143.2006.01242.x
Duncan M, DeVoll-Zabrocki A, Etheredge HR, et al. Blood stream infections in children in the first year after liver transplantation at wits donald gordon medical centre, South Africa. Pediatr Transp 2020;24(2): e13660. https://doi.org/10.1111/petr.13660
Egawa H, Ohdan H, Saito K. Current status of abo-incompatible liver transplantation. Transplantation 2022;107(2):313-325. https://doi.org/10.1097/tp.0000000000004250
Skogsberg Dahlgren U, Herlenius G, Gustafsson B, et al. Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoadsorption. Scand J Gastroenterol 2021;57(1):50-59. https://doi.org/10.1080/00365521.2021.1976269
Botha J, Demetriou G, Fabian J, Etheredge H. Liver transplant for nonresectable colorectal cancer liver metastases in South Africa: A single-center case series. Exper Clin Transp 2020;18(7):842-846. https:// doi.org/10.6002/ect.2020.0064
Bruckmann EK, Beretta M, Demopolous D, et al. Minding the gap—providing quality transplant care for South African children with acute liver failure. Pediatr Transplant 2020;24(8):e13827. https://doi. org/10.1111/petr.13827
Etheredge HR, Turner RE, Kahn D. Attitudes to organ donation among some urban SouthAfrican populations remain unchanged: A cross-sectional study (1993-2013). S Afr Med J 2014;104(2):133-137. https://doi.org/10.7196/SAMJ.7519
Bouter C, Britz R, Strobele B, et al. Adult and paediatric liver transplantation: Wits transplant data 2020. Wits J Clin Med 2023;5(1):41. https://doi.org/10.18772/26180197.2023.v5n1a6
Downloads
Published
Issue
Section
License
Copyright (c) 2024 E U Wessels, J Loveland, H Maher, P Gaylard, B Bobat, A D Mahomed, D Parbhoo, M R Beretta, C Hajinicolaou, P Walabh, S Berkenfeld, D Demopoulos, S Rambarran, B Ströbele, F van der Schyff, J Fabian, L Brannigan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
